Selection of precore mutants during lamivudine treatment in patients with chronic hepatitis B

Hepato-Gastroenterology

Volumn 55, Issue 84, 2008, Pages 1029-1033

  Jae, Youn Cheong ^a   Sung, Won Cho ^a   Jun, Hwan Yoo ^a   Sun, Pyo Hong ^b   Kim, Soo Ok ^b   Wang, Don Yoo ^b   Jin, Hong Kim ^a  

^a Ajou University School of Medicine   (South Korea)

^b GeneMatrix Inc   (South Korea)

Author keywords

Hepatitis B virus (HBV); Lamivudine; Precore mutation; Relapse

Indexed keywords

LAMIVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; PRIORITY JOURNAL; RELAPSE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEROCONVERSION; TREATMENT RESPONSE; VIRUS MUTANT;

ADULT; ANTIVIRAL AGENTS; CODON; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; GENETIC VARIATION; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; KOREA; LAMIVUDINE; MALE; MIDDLE AGED; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; VIRUS REPLICATION;

EID: 47149118771     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Lee WM: Hepatitis B virus infection. The New England journal of medicine 1997; 337(24):1733-1745.
2. Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, Mcgarvey MJ, Makris A et al: Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2(8663):588-591.
3. Karasawa T, Aizawa Y, Zeniya M, Kuramoto A, Shirasawa T, Toda G: Genetic heterogeneity in the precore region of hepatitis B virus in hepatitis B e antigen-negative chronic hepatitis B patients: spontaneous seroconversion and interferon-induced seroconversion. Journal of medical virology 1995; 45(4):373-80.
4. Gunther S, Meisel H, Reip A, Miska S, Kruger D H, Will H: Frequent and rapid emergence of mutated pre-C sequences in HBV from e-antigen positive carriers who seroconvert to anti-HBe during interferon treatment. Virology 1992; 187(1):271-9.
5. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS: Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000; 32(4 Pt 1):803-806.
6. Cho SW, Hahm KB, Kim JH: Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy. Hepatology 2000; 32(5):1163-1169.
7. Suzuki F, Suzuki Y, Tsubota A, Akuta N, Someya T, Kobayashi M, et al: Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy. J Hepatol 2002; 37(6):824-830.
8. Hong SP, Kim NK, Hwang SG, Chung HJ, Kim S, Han JH, et al: Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. J Hepatol 2004; 40(5):837-844.
9. Lee CH, Kim SO, Byun KS, Moon MS, Kim EO, Yeon JE, et al: Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough. Gastroenterology 2006; 130(4):1144-1152.
10. Lee KM, Cho SW, Kim SW, Kim HJ, Hahm KB, Kim JH: Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion. J Viral Hepat 2002; 9(3):208-212.
11. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al: A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. The New England journal of medicine 1998; 339(2):61-68.
12. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, et al: Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999; 29(3):889-896.
13. Lok AS, Akarca U, Greene S: Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal. Proceedings of the National Academy of Sciences of the United States of America 1994; 91(9):4077-4081.
14. Yoo BC, Park JW, Kim HJ, Lee DH, Cha YJ, Park SM: Precore and core promoter mutations of hepatitis B virus and hepatitis B e antigen-negative chronic hepatitis B in Korea. J Hepatol 2003; 38(1):98-103.
15. Hasegawa K, Huang J, Rogers SA, Blum HE, Liang TJ: Enhanced replication of a hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. Journal of virology 1994; 68(3):1651-1659.
16. Ogata N, Miller RH, Ishak KG, Purcell RH: The complete nucleotide sequence of a pre-core mutant of hepatitis B virus implicated in fulminant hepatitis and its biological characterization in chimpanzees. Virology 1993; 194(1):263-276.
17. Carman W, Thomas H, Domingo E: Viral genetic variation: hepatitis B virus as a clinical example. Lancet 1993; 341(8841):349-353.
18. Loriot MA, Marcellin P, Talbodec N, Guigonis V, Gigou M, Boyer N, et al: Low frequency of precore hepatitis B virus mutants in anti-hepatitis B e-positive reactivation after loss of hepatitis B e antigen in patients with chronic hepatitis B. Hepatology 1995; 21(3):627-631.
19. Okamoto H, Tsuda F, Akahane Y, Sugai Y, Yoshiba M, Moriyama K, et al: Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. Journal of virology 1994; 68(12):8102-8110.
20. Buckwold VE, Xu Z, Chen M, Yen TS, Ou JH: Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. Journal of virology 1996; 70(9):5845-5851.